Arzimanoglou A, Brandl U, Cross JH, Gil-Nagel A, Lagae L,
Landmark CJ, Specchio N, Nabbout R, Thiele EA, Gubbay O, The Cannabinoids
International Experts Panel; Collaborators. Epilepsy and cannabidiol: a
guide to treatment. Epileptic Disord. 2020 Feb 1;22(1):1-14. doi:
10.1684/epd.2020.1141.
Abstract
The growing interest in cannabidiol (CBD), specifically a
pure form of CBD, as a treatment for epilepsy, among other conditions, is
reflected in recent changes in legislation in some countries. Although there
has been much speculation about the therapeutic value of cannabis-based
products as an anti-seizure treatment for some time, it is only within the last
two years that Class I evidence has been available for a pure form of CBD,
based on placebo-controlled RCTs for patients with Lennox-Gastaut syndrome and
Dravet syndrome. However, just as we are beginning to understand the
significance of CBD as a treatment for epilepsy, in recent years, a broad
spectrum of products advertised to contain CBD has emerged on the market. The
effects of these products are fundamentally dependent on the purity,
preparation, and concentration of CBD and other components, and consensus and
standardisation are severely lacking regarding their preparation, composition,
usage and effectiveness. This review aims to provide information to
neurologists and epileptologists on the therapeutic value of CBD products,
principally a purified form, in routine practice for patients with intractable
epilepsy.
No comments:
Post a Comment